Haleon PLC

HLN

9.810USD

-0.060-0.61%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

50 / 176

Overall Ranking

160 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

11.007

Target Price

+12.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 31.54.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 41.40%.

Undervalued

The company’s latest PE is 58.37, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 577.49M shares, decreasing 24.84% quarter-over-quarter.

Held by Van Duyn Dodge & E. Morris Cox

Star Investor Van Duyn Dodge & E. Morris Cox holds 155.47M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.10.

The company's current financial score is 8.65, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.65

Change

0



Financials

6.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.21

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 57.78, which is 13.66% below the recent high of 65.67 and -3.54% above the recent low of 59.82.

Score

Industry at a Glance

Previous score

1.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 50/176

No Data

The company’s current earnings forecast score is 8.40, which is higher than the Pharmaceuticals industry's average of 7.96. The average price target for Haleon PLC is 11.20, with a high of 13.60 and a low of 5.88.

Score

Industry at a Glance

Previous score

8.40

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.62, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 10.02 and the support level at 9.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.50

Change

-1.33

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 12.86%, representing a quarter-over-quarter increase of 0.48%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 155.47M shares, representing 3.47% of shares outstanding, with 12.17% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

169.15M

-5.37%

Fidelity Management & Research Company LLC

97.16M

+2.61%

ClearBridge Investments, LLC

32.59M

-0.64%

Harding Loevner LP

23.07M

-4.37%

Fidelity Institutional Asset Management

14.29M

+1.09%

Wellington Management Company, LLP

18.70M

+22.00%

Managed Account Advisors LLC

4.84M

+2.75%

Sculptor Capital Management, Inc

10.85M

+22.09%

Aristotle Capital Management, LLC

8.44M

-3.59%

Parametric Portfolio Associates LLC

7.67M

+8.02%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 6.12, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Haleon PLC

HLN

6.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.